232 related articles for article (PubMed ID: 36424628)
1. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
Xing P; Zhao Q; Zhang L; Wang H; Huang D; Hu P; Sun Y; Shi Y
BMC Med; 2022 Nov; 20(1):453. PubMed ID: 36424628
[TBL] [Abstract][Full Text] [Related]
2. Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.
Ma Y; Pan H; Liu Y; Zhang Y; Hong S; Huang J; Weng S; Yang Y; Fang W; Huang Y; Xiao S; Wang T; Ding L; Cui L; Zhang L; Zhao H
J Thorac Dis; 2022 Dec; 14(12):4751-4762. PubMed ID: 36647478
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Shi Y; Fang J; Hao X; Zhang S; Liu Y; Wang L; Chen J; Hu Y; Hang X; Li J; Liu C; Zhang Y; Wang Z; Hu Y; Gu K; Huang J; Zhang L; Shan J; Ouyang W; Zhao Y; Zhuang W; Yu Y; Zhao J; Zhang H; Lu P; Li W; Si M; Ge M; Geng H
Signal Transduct Target Ther; 2022 Jan; 7(1):25. PubMed ID: 35087031
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
Shi Y; Chen J; Zhang H; Zhang Z; Zhang Y; Wang Z; Zhang S; Zhao J; Liu C; Wang X; Zhao Y; Hu C; Yang L; Hao X; Wang L; Liu Y; Yu Y; Zhao J; Wang M; Zhang L; Sun S; Hu Y; Gu K; Hang X; Shan J; Zhang Y; Tan B; Yang W; Yang R; Si M; Geng H; Li H; Kang X
BMC Med; 2023 Feb; 21(1):72. PubMed ID: 36829154
[TBL] [Abstract][Full Text] [Related]
5. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
6. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
Ma Y; Zhao H; Xue J; Liu L; Yang N; Zhang Y; Yang H; Hong S; Xiong Y; Zhang Z; Zeng L; Pan H; Zhou C; Zhang Y; Wang X; Han X; Wan X; Shao Y; Liu J; Yang Y; Huang Y; Zhao Y; Fang W; Li S; Zhang L
Eur J Cancer; 2022 Sep; 173():238-249. PubMed ID: 35940055
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
8. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
[TBL] [Abstract][Full Text] [Related]
10. Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Sugawara S; Kondo M; Yokoyama T; Kumagai T; Nishio M; Goto K; Nakagawa K; Seto T; Yamamoto N; Kudou K; Asato T; Zhang P; Ohe Y
Int J Clin Oncol; 2022 Dec; 27(12):1828-1838. PubMed ID: 36036294
[TBL] [Abstract][Full Text] [Related]
11. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
Hu X; Cui X; Wang Z; Liu Y; Luo Y; Zhong W; Zhao H; Yao M; Jiang D; Wang M; Chen M; Zheng X; Ding L; Wang Y; Yuan X; Wu P; Hu B; Han X; Shi Y
BMC Cancer; 2023 Apr; 23(1):331. PubMed ID: 37041472
[TBL] [Abstract][Full Text] [Related]
13. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
Yoshida T; Kumagai T; Toyozawa R; Katayama R; Nishio M; Seto T; Goto K; Yamamoto N; Ohe Y; Kudou K; Asato T; Zhang P; Nakagawa K
Cancer Sci; 2023 Sep; 114(9):3698-3707. PubMed ID: 37434391
[TBL] [Abstract][Full Text] [Related]
14. Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study.
Shi Y; Hu X; Li X; Gong C; Wang K; Li Y; Zhang S; Luo Y; Wang P; Jiang L; Meng X; Dong X; Wang H; Yang R; Mei Q; Liu B; Yang L; Sun Y
J Thorac Oncol; 2024 Jan; ():. PubMed ID: 38295954
[TBL] [Abstract][Full Text] [Related]
15. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L
J Thorac Oncol; 2024 Jan; ():. PubMed ID: 38280448
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
[TBL] [Abstract][Full Text] [Related]
17. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Horn L; Infante JR; Reckamp KL; Blumenschein GR; Leal TA; Waqar SN; Gitlitz BJ; Sanborn RE; Whisenant JG; Du L; Neal JW; Gockerman JP; Dukart G; Harrow K; Liang C; Gibbons JJ; Holzhausen A; Lovly CM; Wakelee HA
Clin Cancer Res; 2018 Jun; 24(12):2771-2779. PubMed ID: 29563138
[No Abstract] [Full Text] [Related]
18. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
19. Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT; Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Lau YY; Goldwasser M; Boral AL; Engelman JA
N Engl J Med; 2014 Mar; 370(13):1189-97. PubMed ID: 24670165
[TBL] [Abstract][Full Text] [Related]
20. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]